BioCentury
ARTICLE | Company News

Diamyd Medical, Periphagen Holdings deal

October 15, 2012 7:00 AM UTC

Diamyd will sell its U.S. subsidiary Diamyd Inc. to Periphagen for $1 and a holding of 10% in Periphagen. As part of the deal, Periphagen will acquire IP rights to Diamyd's Nerve Targeting Drug Delive...